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Abstract 
One of the main feature of chronic kidney disease is the development of renal fibrosis. Heparan Sulfate 
(HS) is involved in disease development by modifying the function of growth factors and cytokines and 
creating chemokine gradients. In this context, we aimed to understand the function of HS sulfation in 
renal fibrosis. Using a mouse model of renal fibrosis, we found that total HS 2-O-sulfation was 
increased in damaged kidneys, whilst, tubular staining of HS 3-O-sulfation was decreased. The 
expression of HS modifying enzymes significantly correlated with the development of fibrosis with 
HS3ST1 demonstrating the strongest correlation. The pro-fibrotic factors TGF1 and TGF2/IL1 
significantly downregulated HS3ST1 expression in both renal epithelial cells and renal fibroblasts. To 
determine the implication of HS3ST1 in growth factor binding and signaling, we generated an in vitro 
model of renal epithelial cells overexpressing HS3ST1 (HKC8-HS3ST1). Heparin Binding EGF like 
growth factor (HB-EGF) induced rapid, transient STAT3 phosphorylation in control HKC8 cells. In 
contrast, a prolonged response was demonstrated in HKC8-HS3ST1 cells. Finally, we showed that both 
HS 3-O-sulfation and HB-EGF tubular staining were decreased with the development of fibrosis. Taken 
together, these data suggest that HS 3-O-sulfation is modified in fibrosis and highlight HS3ST1 as an 
attractive biomarker of fibrosis progression with a potential role in HB-EGF signaling. 
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1. Introduction 
Chronic kidney disease (CKD) is a worldwide health problem affecting 8-16% of the world’s population 
[1]. CKD is characterised by glomerulosclerosis and interstitial fibrosis and is caused by a wide range 
of pathologies including metabolic disease, inflammation and vascular damage which finally lead to the 
accumulation of extracellular matrix [2]. There is currently no treatment that can reverse renal fibrosis, 
therefore finding new biomarkers and treatments is one of the major challenges in medicine [2,3].  
Heparan Sulfate (HS) is a sulfated polysaccharide with a structure consisting of repeating units of uronic 
acid (UA) linked to a N-acetyl- or N-sulfo-D-glucosamine (GlcNAc, GlcNS), which can vary in length 
and degree of sulfation. HS is an abundant component of extracellular matrices and cell surfaces, where 
it is found covalently bound to the core protein of HS proteoglycans (HSPG) [4]. HSPGs regulate the 
function of growth factors and chemokines by preventing their proteolysis, regulating receptor 
activation and anchoring them to the extracellular matrix and to the cell surface [5–7]. Due to its role 
in leukocyte recruitment and in the binding and modulation of pro-fibrotic factors such as TGF [8], 
HS plays a crucial role in the development of fibrosis [9,10]. Furthermore, HS has been associated with 
renal tissue remodelling as expression of HSPGs including Collagen XVIII and perlecan is increased in 
interstitial fibrosis of kidney isografts and allografts in rats [11]. In addition, we have previously shown 
increased HS sulfation on the tubular epithelial cell membranes and in the interstitium of kidneys in 
patients with chronic rejection [12].  
HS can be sulfated at the N, 2-O, 3-O and 6-O position. These modifications are key to its function, as 
the negative charge provided by the sulfation modulates HS binding to proteins. HS sulfation in the 
glomerular basement membrane (GBM) has been extensively studied but the role of HS in the 
glomerular filtration is still not fully understood [13,14]. However, it is evident that there is a 
fundamental change in HS composition in pathological conditions [14,15]. In diabetic patients, 
disaccharide analysis of the glomerular basement membrane revealed a decrease in 3-O-sulfation [16]. 
Biopsies from patients with glomerulopathies such as lupus nephritis, membranous glomerulonephritis, 
minimal change disease and diabetic nephropathy showed a decrease in HS by indirect 
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immunofluorescence staining [15]. In contrast, patients with proliferative lupus nephritis had a 
significant increase of N- and 2-O-sulfated HS in their glomeruli [17]. 
Several enzymes are responsible for the biosynthesis and sulfation of HS. The exostosin (EXT) enzymes 
EXT1 and EXT2 are involved in HS polymerisation [18], while the sulfotransferases add sulfate groups 
to the carbohydrate backbone. There are four isoforms of N-deacetylase/N-sulfotransferase (NDST), 
one 2-O-sulfotransferase (HS2ST), seven isoforms of 3-O sulfotransferase (HS3ST) and three isoforms 
of 6-O sulfotransferase (HS6ST) [19–21].  Additionally, HS can be 6-O-desulfated by two endogenous 
sulfatases (SULF) [22]. Changes in the expression of enzymes involved in HS biosynthesis are 
associated with the development of renal dysfunction [23]. Podocyte specific NDST1 knockout led to 
the development of glomerular hypertrophy together with an increase in mesangial area at 6 months 
[24]. Additionally, podocyte specific EXT1 knockout mice showed hypertrophic glomeruli and a 
decrease in highly sulfated HS on the glomerular capillary endothelium [25]. Furthermore, heparanase, 
an enzyme that cleaves HS from HSPG and releases biologically active oligosaccharide fragments, is 
also important in the development of renal diseases [26,27]. Heparanase expression is increased in rats 
with Adriamycin nephropathy [28] and in patients with overt diabetic nephropathy [29]. Heparanase 
KO mice were protected against the development of diabetic nephropathy [30]. 
Although HS 3-O sulfation composition and localisation in the kidney have been previously studied  
[31,32], very little is known about its biological role and possible effects on growth factor function [33]. 
HS3STs are known to generate the binding motif for antithrombin III and HS herpes simplex virus 1 
gD protein, but their activity and substrate specificity are still being studied [34]. These enzymes are 
not homogeneously expressed in the body and there is increasing evidence that their expression changes 
during the development of disease. HS3ST2 and HS3ST4 are mainly expressed in the brain [35,36] and 
there has been interest in HS3ST2 in tauopathies, with its expression increasing in the hippocampus of 
patients with Alzheimer’s disease [37]. HS3ST3 and HS3ST1 are more widely expressed with HS3ST1 
mostly expressed in the brain, heart, lung, spleen, stomach, small intestine, colon, testis and the kidney 
[35,36]. HS3ST1 expression is regulated by a number of factors, with LPS and TNF reducing its 
expression in human microvascular endothelial cells [38],  whereas expression is increased by IL-4 and 
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IL-13 treatment of intestinal epithelial cells [39] and FGF10 treatment of salivary gland epithelia [40]. 
Reports describing the expression of HS3ST1 during renal transplantation show that it is overexpressed 
in tolerant patients [41] and in failing grafts [42]. While the first study examined blood samples, the 
latter analysed tissue expression, which may explain the discrepant findings. These studies did not 
investigate the mechanism underlying the changes in HS3ST1 expression.   
In this study, we have investigated changes in HS sulfation during the development of renal interstitial 
fibrosis in vivo and determined whether these changes were mirrored by the expression of HS modifying 
enzymes. Furthermore, we identified factors that modulate the expression of HS3ST1 in renal cells in 
vitro. Finally, we analysed the implications of the changes in HS3ST1 expression on HB-EGF 
signalling, a growth factor known to stimulate tubular epithelial cells repair [43], cell motility [44] and 
is expressed in renal transplants [45,46]. 
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2. Materials and Methods 
2.1. Animal work 
All experiments were carried out under UK Home Office regulations (PPL60/4521) at the Comparative 
Biology Centre (CBC) in Newcastle University. C57BL/6 mice aged 8-10 weeks were subjected to 
Unilateral Ureteral Obstruction (UUO). The non-ligated kidney was used as control. Mice kidneys were 
harvested at 5 and 10 days post-UUO with 6 animals per group. Each kidney collected was dissected 
for paraffin embedded sections, frozen sections, RNA extraction and HS disaccharide analysis. 
2.2. Cells culture and treatments 
All media were supplemented with 2 mM L-Glutamine, 100 U/mL Penicillin, 100 μg/mL Streptomycin 
(Sigma). The immortalised renal tubular epithelial cell line HK2 (ATCC) was grown in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma, D5671) supplemented with 10% heat inactivated Fetal 
Bovine Serum (FBS). The second cell line of immortalised renal epithelial cells studied was HKC8, 
kindly given by Dr. Racusen [47]. They were cultured in DMEM-F12 (Sigma, D6421) supplemented 
with 5% FBS. NKR-49F (ATCC) were cultured in DMEM supplemented with 5% FBS. All cells were 
grown in a humidified incubator with 5% CO2 at 37°C. 
Cell were seeded in complete media until 80% confluent then in starving medium supplemented with 
0.5% FBS for 16-24 hours. For Western Blot studies, cells were treated with 10 ng/mL HB-EGF (Sigma 
E4643).  For HS3ST1 expression study, all recombinant human cytokines were purchased from 
PeproTech and were active in both human and rats. Cells were treated with either 5 ng/mL TGFβ1 (100-
21C), 10 ng/mL TGFβ2 (100-35B) + 10 ng/mL IL1β (200-01B). 
Human kidney primary proximal tubular epithelial cells (primary PTECs) were isolated from 
macroscopically normal parts of nephrectomy specimens removed for oncological indications (ethical 
approval 13/EM/0311). The resected kidney tissue was collected in sterile RPMI 1640 media (Sigma-
Aldrich) supplemented with 5% FBS and Penicillin (100U/mL) / Streptomycin (100 µg/ml), and was 
immediately transferred to 4°C for subsequent cell isolation procedure. Primary PTECs were isolated 
using Percoll gradient centrifugation protocol as previously reported [48]. Briefly, samples were 
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enzymatically digested with collagenase, mechanically sieved and centrifuged with two discontinuous 
Percoll gradients (1.04 gram/mL and 1.07 gram/mL). This method yielded 1.5 to 2 million cells/gram 
wet weight of tissue specimen. Primary PTECs were maintained in DMEM/HAM F-12 media (Lonza) 
supplemented with insulin, hydrocortisone, GA-1000, adrenaline, T3, transferrin, foetal bovine serum, 
and human epithelial growth factor. Preliminary experiments to characterise the isolated cells showed 
positive staining of epithelial cell markers, such as ZO-1, E-cadherin, K-cadherin and Cytokeratin. The 
isolated cells did not express mesenchymal markers, such as -SMA, Vimentin or Collagen type-1. 
Under light microscope, the cells were hexagonal in shape, and showed “cobblestone-like” appearance 
with the occasional presence of hemicysts or “dome” formation when grown to form a confluent 
monolayer. Moreover, scanning electron microscope images of the isolated cells revealed the presence 
of brush borders, which is a typical feature of kidney tubular epithelial cells. These epithelial 
characteristics were evident up to the first three passages. Only cells in passage two were used in our 
experiments. 
2.3. RNAs extraction and quantitative RT-PCR 
In this study, two methods of RNA extraction were used. A column-based method using the Qiagen 
RNeasy Plus Mini Kit for cells following manufacturer’s instructions and a Trizol/Chloroform method 
for mouse tissue. Briefly, mouse kidney tissue was homogenised in TRI reagent (Ambion) using the 
Tissue Lyser II by Qiagen. RNA was isolated separated from the protein by adding chloroform (AnalaR) 
and mixed by inversion. Samples were centrifuged, and the aqueous phase mixed with isopropanol. The 
RNAs pellet was suspended in 1mL of 70% ethanol, centrifuged and air dried before being suspended 
in 30μL of RNAse free water (Ambion). To avoid gDNA contamination 1 μg of sample was treated 
with RQ1 DNAse (Promega) for 30 minutes at 37°C. Next, samples were treated with DNase stop 
solution (Promega) 10 minutes 65°C. Complementary DNA (cDNA) was generated using Tetro cDNA 
synthesis kit (Bioline, BIO-65043) following the manufacturer’s instruction. TaqMan probes 
(Thermofisher) were used to amplify cDNA (see supplementary data, table 1). HPRT was used as 
housekeeping gene to normalize CT values. For the in vivo work, samples were analysed in six 
biological replicates done in triplicate and analysed using the comparative ΔΔCT method. For the in 
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vitro work, unless specified, samples were analysed in three biological replicates done in triplicate and 
analysed using the comparative ΔΔCT method. 
2.4. HS disaccharide analysis from cells 
Subconfluent HKC8 cells were cultured with 200 µCi/ml Na235SO4 (Perkin Elmer) for 24 hrs at 37°C. 
After incubation, the culture medium was removed and frozen at –20 °C for further use. The cell layer 
was washed twice with cold PBS and solubilized at 4°C for 60 min in 1% Triton TX-100, 50 mM 
Tris/HCl pH (7.4), 0,15 M NaCl and proteinase inhibitors. After centrifugation, the supernatant was 
collected and an aliquot (100µl) was removed for protein determination using the BCA protein 
determination kit (Pierce). The remaining supernatant was used for purification of the 35S-labeled 
polysaccharides. Polysaccharide chains were released from the core protein by treatment with 0.5 M 
NaOH over night at 4°C. After completed ß-elimination, the samples were neutralized with 4 M HCl. 
Samples were adjusted to 0.15 M NaCl and applied to a 0.5 ml DEAE-Sephacel column equilibrated in 
0.15 M NaCl, 0.05 M Tris-HCl pH 7.4, 0.1% Triton X-100. The column was washed with the 
equilibration buffer, followed by 0.15 M NaCl, 0.05 M acetate buffer pH 4.0, 0.1% Triton X-100 and 
0.05 M Tris/HCl pH 7.5. Finally, the labeled GAG chains were eluted with 1.5 M NaCl and desalted 
by gel chromatography using PD-10 columns (Sephadex G-25, Amersham Biosciences) in H2O.  
Purified 35S-labeled HS chains were cleaved at N-sulfated GlcN residues by deamination with nitrous 
acid at pH 1.5 followed by reduction with NaBH4. Labeled deamination products were fractionated by 
gel chromatography on Sephadex G-15 (1 cm x 180 cm) in 0.2 M NH4HCO3. Fractions corresponding 
to oligo- and disaccharides were collected and desalted by lyophilization. HS disaccharides analysis 
was performed with HPLC using a Whatman Partisil 10-SAX column eluted with aqueous KH2PO4 of 
stepwise increasing concentration at a rate of 1 ml/min [49]. 
2.5. HS disaccharide analysis from renal samples 
Pooled frozen kidney tissue were collected to generate four groups (D5 Control, D5 UUO, D10 Control, 
D10 UUO) with each group containing between 35 to 62 mg of frozen tissue. Samples were lysed, 
digested, purified and analysed as previously described [50]. Briefly, all samples were mechanically 
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lysed in 50 mM Tris Buffered Saline, 2 mM EDTA, 6 M Urea and dialysed against 25 mM Tris, 5 mM 
EDTA pH 7.8. Following protein degradation in 2 mg/ml of pronase 24h at 37°C and two treatments 
with 5% v/v trichloroacetic acid, supernatants were washed with 50% v/v diethylether and run onto a 
DEAE-Sephacel column equilibrated in 20 mM phosphate pH 6.5. Samples were eluted in 20 mM 
phosphate, 1 M NaCl pH 6.5 and desalted using a PD-10 column in H2O, then lyophilised. GAGs were 
then resuspended in 100 mM sodium acetate, 0.5 mM CaCl2, pH 7.1 and digested with 10 mU of 
heparinase I (Grampian enzymes) overnight at 30°C, then with 10 mU heparinase II and 10 mU 
heparinase III (Grampian enzymes) for 24h at 37°C. Following digestion, disaccharides analysis was 
performed by reverse-phase ion-pair high-performance liquid chromatograph [50] in triplicate. 
2.6. Stable transfectants 
Plasmid EX-TO223-M13 containing flag tagged HS3ST1 enzyme sequence was purchased from 
GeneCopoeia. Bacterial transformation of E.coli DH5α (Invitrogen) was performed using the heat 
shock method. Bacterial cells lysis and plasmid purification were performed using Plasmid Mini Kits 
(Qiagen). To generate an empty plasmid (plasmid without HS3ST1 sequence), 3 μg of plasmid were 
digested with 30U of BsrGI (Bsp 1407I, ThermoFisher). The digested plasmid was extracted using 
QIAquick Gel Extraction Kit Plasmid extraction. The final plasmid was ligated 3h at room temperature 
using T4 DNA ligase.  
Cells transfections were performed using Effectene Reagent (Qiagen) in combination with an enhancer 
and a DNA-condensation buffer. The following day, fresh media containing 200 µg/mL of selective 
antibiotic G418 was added to the transfected cells. Colonies were isolated using cloning cylinders.  
2.7. Western Blotting 
Cellular proteins were extracted using CelLytic M (Sigma) complemented with protease (Complete 
Mini Protease Inhibitor Cocktail, Roche) and phosphatase (Roche) inhibitors. Between 10 to 50 μg of 
protein extract samples were denaturated and electrophoretically separated by Sodium Dodecyl Sulfate 
(SDS) Polyacrylamide gel electrophoresis, then transferred by semi dry transfer (BioRad) to 
nitrocellulose membranes (BioRad). Membranes were blocked for 1h at room temperature in 0.1% 
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Tween Tris-buffered saline (TBS) with 5% fat free milk or 5% Bovine Serum Albumin (BSA) when 
looking at phosphorylated proteins and probed overnight at 4°C using the following primary antibodies 
diluted in blocking buffer (STAT3 Y705 ab76315 Abcam 1:20 000, alpha tubulin T6074 Sigma 
1:4000). Following overnight incubation, membranes were washed in TBS 0.1% Tween and incubated 
with the corresponding secondary antibodies conjugated with HorseRadish Peroxidase (R&D 1:1000), 
for 1 hour at room temperature. Finally, membranes were washed again, and bands were visualized by 
enhanced chemiluminescence and exposed to X-ray films.      
2.8. Staining 
Cells were fixed in ice-cold methanol for 5 minutes at -20°C, gradually rehydrated with PBS (Sigma, 
P4417), blocked with 5% BSA in PBS for 2 hours at room temperature and incubated overnight with 
primary antibodies (Flag Tag 2368 Cell Signalling 1:3000, GM130 Abcam 1:70). Slides were washed 
with PBS, then incubated for 2h at room temperature with the corresponding secondary antibody (anti-
mouse Alexa fluor 488 ThermoFisher 1:100, anti-rabbit Dylight550, Immunoreagents 1:100). Finally, 
slides were washed in PBS and mounted with liquid mounting medium containing DAPI (Vectashield). 
The use of fluorescently labeled Antithrombin III (AT) for detecting HS 3-O-sufation has been 
previously described [31]. Fluorescently labeled AT with Alexa fluor 647 was generated following 
manufacturer’s instructions (ThermoFisher Scientific, A20173). Staining specificity was assessed with 
heparin competition. Cryosections of 7 m thickness were fixed in acetone and blocked with 1% BSA 
in PBS for 20 minutes at room temperature. Slides were incubated for 1 hour with labeled antithrombin 
III and washed three times with blocking buffer. Slides were mounted using Diamond antifade with 
Dapi. 
Mouse kidneys were dissected and fixed in 10% formalin solution and embedded in paraffin. Serial 
tissue sections of 4 µm thickness were cut and mounted onto slides. Peptide retrieval was performed by 
microwaving the slides in EDTA buffer. Sections were blocked 10 minutes with 2% FBS in PBS and 
incubated overnight at 4°C with primary antibody (HB-EGF ab192545 Abcam 1:200, HS4C3 1:5 given 
by Toin van Kuppevelt, Radboud University, Netherlands). The next day, sections were washed in PBS, 
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then incubated with secondary antibody (anti VSV C7706 sigma, Dylight 550 Immunoreagent) diluted 
in PBS for 1-2 hours at room temperature. Sections were then washed in PBS, incubated with Sudan 
Black for 20 minutes in the dark at room temperature and finally washed in PBS before mounting with 
VECTA shield DAPI liquid mounting medium.  
Sirius red and Haematoxylin Eosin staining were performed following standard procedures. 
All images were analysed using Fiji software.  Fluorescent imaging was performed using Leica LCM 
microscope, Zeiss Axioimager, Nicon A1R confocal microscope.  For Sirius red quantification, images 
were analysed using LeicaQWin analysis software with 10 cortex fields analysed per section for each 
kidney. 
2.9. Software 
Graphs were created using Microsoft Excel and GraphPad Prism 6.0. Diagrams were generated using 
Servier Medical Art images (http://servier.com/Powerpoint-image-bank).  
2.10. Statistical Analysis 
Results are expressed as mean ± Standard Deviation. Statistical evaluations were performed using 
GraphPad Prism 6.0. Significant results were considered when P<0.05 (*), P<0.01 (**) and P<0.001 
(***). P values were calculated using two tailed unpaired student’s t-test with Welch’s correction. 
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3. Results 
3.1. Unilateral Ureteral Obstruction induces interstitial fibrosis and modulates HS sulfation 
To assess the structural changes and fibrosis development in the UUO model, kidney sections were 
stained with H&E and Sirius red. Sections from day 5 (D5) and 10 (D10) showed tubular dilatation and 
tubulointerstitial expansion (figure 1A). Additionally, there was a significant increase in interstitial 
fibrosis as assessed by Sirius red staining when compared with control kidneys at D5 and D10 UUO 
(p<0.05 and p<0.001 respectively) (figure 1B-C). To further address the relevance of the UUO model 
for HS studies, HS sulfation was evaluated. As shown in figure 1D total HS O-sulfation, measured by 
reverse-phase ion-pair HPLC, increased in UUO by 13.7% at D5 and 6.5% at D10. Assessment of the 
pattern of HS sulfation showed an increase of total 2-O-sulfation by 45.3% at D5 and 19.2% at D10 
(figure 1E). HS disaccharide composition (supplementary data, figure 1) revealed an increase of the 
disulfated disaccharides ΔUA.2S-GlcNS but a decrease in the monosulfated disaccharides ΔUA-
GlcNAc.6S and in the disulfated disaccharides ΔUA-GlcNS.6S at D5 and D10 UUO. Overall, these 
results show that UUO-induced renal fibrosis results in changes in HS disaccharide sulfation patterns 
which could potentially translate in altered protein binding.  
3.2. HS sulfotransferases and sulfatases mRNA expressions are altered in UUO 
In order to investigate whether the increase in HS sulfation was mirrored by a change in the levels of 
HS sulfotransferases and sulfatases, their expression levels in control and UUO kidneys was analysed 
by real time qPCR. RNA expression analysis was chosen over protein analysis as endogenous protein 
levels can be difficult to measure with the antibodies currently available [51]. The increase of HS 2-O-
sulfation was reflected by a significant increase of HS2ST1 expression at D10 of UUO (p<0.01) (figure 
2A). Additionally, there was a small but significant increase of SULF1 expression at D5 (p<0.05) 
(figure 2B) but no detectable expression of HS 6-O-sulfotransferase 1 (HS6ST1) (data not shown). The 
level of HS3ST3A expression shown in figure 2C decreased at D5 and D10 but only significantly at D5 
(p<0.05). There was a significant increase in expression of HS3ST1 at both D5 and D10 UUO (figure 
2D) (p<0.001). Furthermore, HS3ST1 expression correlated significantly with the degree of fibrosis 
 13 
assessed by Sirius red staining, Pearson correlation coefficient r=0.7881 with p<0.001 (figure 2E). The 
other enzymes, HS2ST1, HS3ST3A and SULF1 also showed a correlation with Sirius red staining 
(supplementary data, figure 2). Taken together, these results suggest that there is an association between 
the level of fibrosis and the expression of HS modifying enzymes. Because of the highest correlation 
between HS3ST1 and fibrosis, we then explored the functional implication of this change. 
 
Figure 1. The development of interstitial fibrosis at D5 and D10 of UUO is accompanied by a change 
in HS sulfation. Representative images of Haematoxylin and Eosin staining (A) and Sirius red staining 
(B) of cortex from control unobstructed kidney, D5 UUO and D10 UUO. Scale bars represent 100 µm. 
Interstitial fibrosis was assessed by Sirius red staining (C). N=6 with 10 cortex fields analysed per 
section for each kidney, two-tailed unpaired t test, p<0.05 (*), p<0.001 (***). HS sulfation of 6 pooled 
control unobstructed kidney, D5 UUO and D10 UUO is represented as percentage of total disaccharides 
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with error bars from technical replicates. Total O-sulfation (D) and total 2-O-sulfation (E). Results are 
represented as mean ±SD. 
 
Figure 2. HS sulfotransferases are modulated at D5 and D10 UUO. Expression was adjusted to HPRT1 
expression and normalised to the mean of controls (MC) N=6. Two-tailed unpaired t test with Welch’s 
correction with p<0.05 (*), p<0.01 (**) p<0.001 (***). The Pearson’s correlation coefficient was 
generated with the data from HS3ST1 expression and results from Sirius red staining. 
3.3. Localisation of antithrombin binding HS within control and fibrotic kidneys 
The purpose of analysing antithrombin III binding to the kidney was to localise HS 3-O-sulfation 
specifically resulting from HS3ST1 and HS3ST5 activity. As HS3ST5 is expressed at very low levels 
in the kidney [35,52], AT binding can be used as a surrogate marker of HS3ST1 activity. AT binding 
was seen in the luminal surface of blood vessels, on tubules, around Bowman’s capsule and at the 
vascular pole of the glomerulus (figure 3). In D5 UUO kidney AT binding was not changed in blood 
vessels and could be observed within the expanded tubulointerstitium (figure 3D). The overall tubular 
staining decreased. The specificity of AT binding was assessed by competition with soluble heparin, 
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which blocked AT binding to tissue sections (supplementary data, figure 3). The reduced tubular 
binding of AT, and by implication reduced 3-O sulfated HS, is despite the increased expression of 
HS3ST1 seen in UUO kidneys. The increase of HS3ST1 expression might originate from other cells 
within the kidney including endothelial that produce AT binding HS [53] or M2 macrophages that 
express high levels of HS3ST1 [54,55] and are prominent in the UUO model [56]. However, the 
decrease in HS 3-O-sulfation observed in the tubular compartment was unexpected and further studied. 
 
Figure 3. HSPG staining in control and fibrotic renal sections. Representative images of antithrombin 
III (AT) staining on cryosections from control kidney (A, C) and D5 UUO (B, D). AT was labelled with 
Alexa fluor 647. AT binding was detectable around Bowman’s capsule (⤏), on blood vessels (❍), on 
the tubular basement membrane (➝), at the vascular pole of the glomerulus (△) and in the expanded 
interstitium at D5 UUO (✩). N=6 with at least 5 cortex fields analysed per section for each kidney. 
Scale bars represent 100 and 50 µm. 
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3.4. Modulation of HS3ST1 expression by TGF1, TGF2/IL1 in renal epithelial cells and renal 
fibroblasts 
To better understand the role of HS3ST1 in the development of fibrosis, we studied factors influencing 
HS3ST1 expression in the kidney. Primary human tubular epithelial cells screened for expression of 
HS3ST-family members by real time qPCR showed that HS3ST1 was the predominant enzyme, 
followed by HS3ST3A. HS3ST6 and HS3ST3B were expressed at low levels (figure 4A). More 
replicates may have identified differences in expression of the less abundant enzymes. To understand 
what modulates HS3ST1 expression in renal tubular epithelial cells, HK2 cells were treated with 
5ng/mL TGF1. HS3ST1 expression was downregulated after 6 hours (p<0.05) and 48 hours (p<0.05) 
of treatment. HK2 cells treated with a  pro-fibrotic combination of TGF2 (10 ng/mL) and IL1 (10 
ng/mL) [57], also showed significant downregulation of HS3ST1 after 6 hours (p<0.05) and 24 hours 
(p<0.01) of treatment. This downregulation in the expression of HS3ST1 in tubular cells in response to 
pro-fibrotic stimuli is consistent with the reduced AT binding evident within the tubular compartment 
during the development of fibrotic disease. The down regulation of HS3ST1 expression was more 
pronounced in the renal fibroblast cell line NRK-49F (figure 5), with a significant decrease at 6 hours 
and 24 hours with both TGF1 and combined TGF2/IL1 (p<0.05 and p<0.01 respectively).  In view 
of the reduction in tubular H3ST1 expression and the reduction in 3-O sulfation that is likely to result 
from this change, we next explored the function of 3-O sulfated HS in tubular cells. 
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Figure 4. HS3ST1 expression in primary tubular epithelial cells isolated from human kidneys and 
immortalised renal epithelial cells HK2. Primary tubular epithelial cells were isolated from 
macroscopically healthy parts of the kidney N≥2. Results are displayed as log 2 of HS3ST1 fold change 
normalised to HPRT1 (A). HK2 cells were incubated 24h in 0.5% FBS and treated for 3, 6 24 and 48 
hours with 5 ng/mL TGFβ1 (B) and 10 ng/mL TGFβ2 IL1β (C) or maintained in media alone (CTL). 
Results are expressed by mean ±SD N=3 and were normalised to the mean of controls (MC). Two-
tailed unpaired t test with Welch’s correction with p<0.05 (*), p<0.01 (**). 
 
Figure 5. HS3ST1 expression is decreased in immortalised rat fibroblast NRK-49F cells following 
profibrotic treatments. Cells were incubated 24 hours in 0.5% FBS and treated for 3, 6 and 24 hours 
with 5 ng/mL TGFβ1 (A) and 10 ng/mL TGFβ2 IL1β (B) or maintained in media alone (CTL). Results 
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are expressed by mean ±SD N=3 and were normalised to the mean of controls (MC). Two-tailed 
unpaired t test with Welch’s correction with p<0.05 (*), p<0.01 (**). 
3.5. Identification of HB-EGF as a potential growth factor modulated by HS 3-O-sulfation 
The renal epithelial cell line HKC8 was stably transfected with either an empty plasmid (HKC8-CTL) 
or with a plasmid containing the HS3ST1 sequence (HKC8-HS3ST1). HKC8-CTL and HKC8-HS3ST1 
were screened for protein expression and localisation by immunofluorescence (figure 6A). HS3ST1-
flag co-localised with the cis Golgi and around the nucleus. To address the functionality of the HS3ST1 
present in the HKC8-HS3ST1 cells, HS disaccharide analysis was performed after metabolic labeling 
of HKC8-CTL and HKC8-HS3ST1 (figure 6B). There was no detectable HS 3-O-sulfation in the 
HKC8-CTL but after transfection with HS3ST1, approximately 3.7% (figure 6B) and 1.6% 
(supplementary data, figure 4) of total 35S labelled disaccharides eluted as 3-O-sulfated disaccharides 
in two different clones of HKC8-HS3ST1. The exact nature of the disaccharides needs to be further 
identified. However, its elution position and resistance to beta-glucuronidase (data not shown) indicates 
that this peak (eluting at approximately 80 minutes) represents IdoA-GlcNS3S6S in the intact 
polysaccharide. HB-EGF is known to bind to HSPG and can signal through STAT3. The signalling 
pattern was studied by assessing the phosphorylation of STAT3 (Y705). HB-EGF induced 
phosphorylation of STAT3 after 5 minutes of stimulation, which then diminished by 1 hour in HKC8-
CTL. However, HKC8-HS3ST1 showed a strong signal at 5 minutes, with continued phosphorylation 
at 1 hour in two clones (figure 6C). Taken together, these data show that the overexpression of HS3ST1 
can affect HB-EGF signalling. The relevance of this finding in vivo was further studied using the UUO 
model.  
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Figure 6. HS3ST1 overexpressing cells have more HS 3-O-sulfation and a different HB-EGF signalling. 
In stably transfected HKC8 cells, HS3ST1 expression was assessed by immunofluorescence (A) 
HS3ST1-FLAG is shown in red and GM130, a cis Golgi membrane marker, in green. Scale bar 
represents 50 µm. HS disaccharide analysis (B) showed no 3-O-sulfation in the mock (HKC8-CTL) and 
a small amount in the transfected cells HKC8-HS3ST1 (➔). HB-EGF signalling via P-STAT3 was 
analysed at 5 minutes and 1 hour in mock transfected cells HKC8-CTL and in two different clones of 
HS3ST1 transfected cells, HKC8-HS3ST1, N=3 (C). 
3.6. Total HS 3-O-sulfation and HB-EGF staining in renal fibrosis 
HB-EGF staining was predominantly found on the basement membranes of tubules. The staining was 
not uniform, with some cortical tubules, most likely proximal tubules, staining more strongly than 
others (figure 7). A similar staining was observed at D5 and D10 UUO, but with a noticeable decrease 
in intensity (figure 7). Total HS 3-O-sulfation was analysed using the phage display antibody HS4C3, 
which recognises highly sulfated HS when 3-O-sulfation is present. The staining was similar to the AT 
staining but with a more intense staining in the glomerulus. Furthermore, and in agreement with the 
results from the AT staining (figure 3), the staining for HS 3-O-sulfation decreased during the 
development of fibrosis. In conclusion, both HB-EGF and HS 3-O-sulfation are present on the tubular 
basement membrane and both are decreased during the development of fibrosis. However, both staining 
did not seem to colocalise. 
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Figure 7. Staining of HB-EGF and total HS 3-O-sulfation. Representative images of HB-EGF and 
HS4C3 staining on paraffin embedded sections of control tissues, D5 UUO and D10 UUO. HB-EGF 
staining was mainly present on the tubular basement membrane. The HS4C3 antibody, which stains 
heavily sulfated HS, showed glomerular, vascular and tubular staining. N=6 with 10 cortex fields 
analysed per section for each kidney. Scale bars represent 100 µm. 
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4. Discussion 
We hypothesise that, changes in HS O-sulfation in diseased kidneys alters growth factor binding and 
activity, potentially promoting either repair or fibrosis. We have shown here that there are changes in 
the pattern of HS sulfation during the development of renal fibrosis. Total HS O-sulfation was increased 
mainly due to an increase in 2-O-sulfation. Our results are consistent with the increase of HS 2-O-
sulfation observed in tissue from patients with idiopathic pulmonary fibrosis [58] in which its role 
during tissue remodelling was proposed. 2-O-sulfation is known to be important for binding multiple 
growth factors for example members of the FGF family [59,60]. Due to the lack of HS 3-O-sulfation 
standards for the tissue disaccharides analysis, we could not analyse 3-O-sulfation during the evolution 
of UUO.  Altered HS expression may be an attempt to increase growth factor activity and promote 
repair. However, in the context of persistent or repeated injury, the outcome may be fibrosis and loss of 
function. 
The increase in HS 2-O-sulfation was mirrored by an increase in HS2ST1 expression. Surprisingly, 
HS6ST1 expression was too low to be analysed but the HS sulfatase SULF1, that removes 6-O-sulfate 
groups, was also increased in UUO tissue. The increase in SULF1 expression can be explained by the 
presence of TGF1 in fibrotic tissue, a growth factor known to induce SULF1 expression [61]. 
Furthermore, HS3ST3A expression was decreased in renal fibrosis while HS3ST1 expression was 
increased and showed a strong correlation with the amount of fibrosis. SULF1 and HS3ST1 expression 
were previously found to be increased in fibrotic liver and in patients with hepatocellular carcinoma 
[62]. Taken together, these data highlight the potential of HS enzymes as markers of disease 
development.  
Recently, there has been an increased interest in the function of HS 3-O-sulfation. In mouse embryos, 
HS 3-O-sulfation supported stem cell differentiation [63]. In the brain, HS3STs were found to regulate 
axonal growth cone collapse in mice [64] and neuronal development in Caenorhabditis elegans [65]. 
Furthermore, HS3STs have been extensively studied in cancer [66–68]. The impact of the increase of 
HS3ST1 expression was analysed with staining for 3-O-sulfation. There was an overall decrease in HS 
3-O-sulfation in UUO tissue, particularly in the tubular compartment. There are several potential 
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explanations for this decrease. First, the decrease in 3-O-sulfation might be explained by the presence 
of highly 2-O sulfated disaccharides that prevent HS3ST1 action and therefore by a low level of suitable 
HS precursor disaccharides as has been described in glomerular epithelial cells [31]. The increase of 
HS3ST1 mRNA might be an unsuccessful attempt to increase the level of HS 3-O-sulfation. Second, 
HS 3-O-sulfation was only analysed by immunofluorescence and potentially the 3-O-sulfation was 
masked by growth factors bound to it. Lastly, an increase in HS3ST1 expression may occur in 
endothelial or infiltrating immune cells such as macrophages, masking a reduction in tubular cell 
HS3ST1 expression. HS3ST1 expression could be increased in some cells but decreased in others.  
This study also aimed to identify regulators of HS3ST1 expression. TGF1 is known to be a pro-fibrotic 
factor [69] and TGF2/IL1 are implicated in endothelial to mesenchymal transition, a mechanism that 
contributes to fibrosis [57]. Both treatments downregulated HS3ST1 expression in renal fibroblasts and 
renal epithelial cells. Other enzymes such as SULF1 and SULF2 have been shown to be modulated by 
TGF1 [61] and heparanase is implicated in the regulation of TGF1 expression in tubular cells [70]. 
Taken together, these data show a relationship between TGF signalling and the expression of HS 
modifying enzymes. HS sulfation is known to influence protein binding and it is not surprising that pro 
fibrotic factors would be implicated in its regulation. Although we have looked at epithelial cells and 
fibroblasts, expression in tissues will be influenced by other cell types as well. Indeed, previous studies 
have shown that HS3ST enzyme expression by endothelial cells [38] and immune cells [71] is controlled 
by pro-inflammatory factors.  
In order to study the effect of HS3ST1 expression on growth factor binding, we developed an in vitro 
model of renal epithelial cells overexpressing HS3ST1. Overexpression of HS3ST1 had an effect on 
HS disaccharide composition including a small but reproducible increase in HS 3-O-sulfation (up to 
3.7%) (figure 6 and supplementary data figure 4). This level of sulfation might seem low, but HS 3-O 
sulfation is a rare modification. In previous work on anticoagulant HS chains, 3-O sulfated glucosamine 
residues represented around 1% in porcine endothelial cells [53] and 6% in follicular fluid [72]. In CHO 
cells overexpressing HS3ST1, HS containing AT binding site represented 4% of the total HS [73].  
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Very little is known about the effect of 3-O-sulfated HS on growth factor function. HB-EGF can bind 
EGF receptor and induce STAT phosphorylation [74]. This happens rapidly and in control cells the 
response diminishes by 1 hour. In contrast, in cells overexpressing HS3ST1 the STAT phosphorylation 
is evident at 1 hour, suggesting that the cellular response to HB-EGF is altered by the presence of HS 
3-O-sulfation. The mechanism of this delayed response remains to be elucidated, but a previous paper 
suggested that a delayed response to HB-EGF could be mediated by a second messenger such as IL-6 
[75]. HB-EGF plays a role in cellular repair [43] and was found to be protective in the development of 
liver fibrosis [76,77]. A decrease in tubular 3-O-sulfated HS staining was seen together with a decrease 
in HB-EGF during UUO. This could affect the capacity for tubular repair and worsen the severity of 
injury. It is also possible that in addition to reduced 3-O-sulfation, other structural changes in HS such 
as the increase in 2-O-sulfation are affecting HB-EGF binding. Further studies are required to elucidate 
precisely which HS structures can modify HB-EGF binding. 
 
Figure 8. The complex regulation of HS3ST1 in fibrosis. HS3ST1 expression is strongly modulated in 
fibrosis. While in vivo data showed a strong correlation between HS3ST1 expression and the 
development of fibrosis, in vitro data showed a decreased expression following TGFβ1 and 
TGFβ2/IL1β treatment. Graphical illustrations were produced using Servier Medical Art 
(www.servier.com). 
In conclusion, we believe this study has highlighted the complexity of the regulation of HS 3-O-
sulfation and its potential role in renal fibrosis (figure 8). The strong correlation between the increase 
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of HS3ST1 expression and the development of fibrosis, the changes in sulfation patterns during disease 
and the functional consequences of these changes all highlight the importance of studying HS 3-O- 
sulfation. A better understanding of HS biology may lead to more effective strategies to measure or 
modify sulfation for diagnostic or therapeutic benefit. 
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 Supplementary data 
Supplementary figure 1. HS sulfation of 6 pooled control unobstructed kidney, D5 UUO and D10 
UUO is represented as percentage of total disaccharides with error bars from technical replicates. 
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Supplementary figure 2. HS modifying enzymes correlation to Sirius red staining.  
 
Supplementary figure 3. Antithrombin III staining specificity was assessed on mouse kidney tissue by 
incubating 1 hour with labelled ATIII or with ATIII and 20 µM heparin. The ATIII staining was 
abolished by incubating with 20 µM of heparin. Scale bars represent 100 µm. 
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Supplementary figure 4. HS disaccharide analysis of a different overexpressing cellular clone than 
shown in figure 6B showed 1.6% HS 3-O-sulfation (➔) 
Species Gene name Gene Symbol Reference
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 3B1 HS3ST3B1 Hs01391447_m1
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 1 HS3ST1 Hs00245421_s1
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 3A1 HS3ST3A Hs00925624_s1
Human Hypoxanthine guanine phosphoribosyl transferase HPRT1 Hs02800695_m1
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 1 HS3ST1 (for plasmid) Hs01099196_m1 
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 6 HS3ST6 Hs03007244_m1
Mouse Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1 Mm01964038_s1
Mouse Heparan sulfate (glucosamine) 3-O-sulfotransferase 3A HS3ST3A1 Mm000780907_s1
Mouse Hypoxanthine guanine phosphoribosyl transferase HPRT Mm03024075_m1
Mouse Sulfatase 1 SULF1 Mm00552283_m1
Mouse Heparan Sulfate 2-O-sulfotransferase 1 HS2ST1 Mm00478684_m1  
Supplementary table 1. Gene expression was determined using TaqMan probes from ThermoFisher. 
Hs: Homo sapiens, Mm: Mus musculus. Suffix m indicates probes that are designed between two exons 
whereas s defines probes that bind within a single exon. 
 
